Neuroleptic activity and dopamine-uptake inhibition in 1-piperazino-3-phenylindans.
A series of 1-piperazino-3-phenylindans was synthesized and tested for neuroleptic and thymoleptic activity. Neuroleptic activity was found only in trans racemates and was associated with one of the enantiomers only. The potent and long-acting neuroleptic compound trans-4-[3-(4-fluorophenyl)-6-(trifluoromethyl)indan-1-yl]-1-piperazineethanol (Lu 18-012, tefludazine) was developed by systematic variation of structural components. Thymoleptic activity was optimized, especially with respect to dopamine-uptake inhibition. No geometrical stereoselectivity was found with regard to dopamine-uptake inhibition, but a high enantioselectivity could be demonstrated for both cis and trans racemates. The most potent compounds were 1-piperazino-3-(3,4-dichlorophenyl)indans with IC50 values of about 2nM for inhibition of dopamine uptake.
D000661:Amphetamine / Q000037:antagonists & inhibitors; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001681:Biological Assay; D001692:Biological Transport / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D006220:Haloperidol / Q000378:metabolism; D007189:Indans / Q000138:chemical synthesis / Q000494:pharmacology*; D007192:Indenes / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009638:Norepinephrine / Q000378:metabolism; D010879:Piperazines / Q000138:chemical synthesis / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism; D013329:Structure-Activity Relationship; D013574:Synaptosomes / Q000378:metabolism
D014150:Antipsychotic Agents; D007189:Indans; D007192:Indenes; D010879:Piperazines; D011954:Receptors, Dopamine; D012701:Serotonin; D000661:Amphetamine; D006220:Haloperidol; D004298:Dopamine; D009638:Norepinephrine